Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB100 PK/PD in Recurrent Glioblastoma
NCT03027388Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LB-100 in glioblastoma (GBM), astrocytoma, Oligodendroglioma (OG), sponsored by National Cancer Institute. Started Jan 2019; status: completed.
02
Drugs
LB-100
03
Conditions
glioblastoma (GBM)astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT03027388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027388.